What Health Issues Does Melatonin Cause?

Melatonin is sold without a prescription in the US and Canada and widely described as natural and harmless. It isn't quite either. A systematic review of 2,130 patients confirmed it causes documented side effects — and a 2025 American Heart Association preliminary study raised new questions about cardiovascular risk in long-term users. Most of the health concerns tied to melatonin are real, manageable, and dose-dependent. Understanding them specifically, rather than in vague generalities, is what allows you to use it safely — or decide not to.

Table of Contents

1. Documented Side Effects: What RCTs Show
2. Hormonal and Endocrine Effects
3. Cardiovascular Risks: The 2025 AHA Study Explained
4. Drug Interactions That Cause Health Problems
5. Special Risks in Children and Adolescents
6. The Mislabelling Risk: Taking More Than You Know
7. Reducing Melatonin Health Risks Through Dose Precision
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. Documented Side Effects: What RCTs Show

The most reliable evidence for melatonin's health effects comes from randomised controlled trials, where participants taking melatonin are directly compared to a placebo group under controlled conditions. A 2019 systematic review aggregating data from 2,130 patients identified four adverse effects that consistently exceeded placebo rates: daytime sleepiness (1.66%), headache (0.74%), other sleep disturbances (0.74%), and dizziness (0.74%). No life-threatening or clinically serious adverse events were identified. These are real health effects — but they affect fewer than 2 in 100 users at appropriate doses and are mild in nature.

Beyond the top four, a separate systematic review of melatonin's clinical safety record identified additional reported adverse events — nausea, vivid dreams, irritability, and mild hypothermia — most of which were tied to higher doses or extended-release formulations. The pattern across the literature is consistent: melatonin's documented health effects are dose-sensitive. Side effects become more common and more pronounced as the dose increases above the physiological range (above 0.3–1mg), and most resolve on stopping or reducing the dose.

What gets less attention is the symptom that most users actually notice: next-morning grogginess. This is not typically captured as a clinical adverse event in RCTs, but it is the most common complaint in real-world use. It results from taking too much melatonin too late — the hormone remains active in the bloodstream past waking time, suppressing the brain's alertness signals. Standard US retail products contain 5–10mg per dose; the body naturally produces 0.1–0.3mg at peak nighttime. The mismatch between commercial dose conventions and physiological reality is where most of melatonin's everyday health complaints originate.

2. Hormonal and Endocrine Effects

Melatonin is a hormone, and like all hormones, it does not operate in isolation. The NIH notes that because melatonin is a hormone, it's possible that supplements could affect hormonal development — including puberty timing, menstrual cycle regulation, and prolactin levels — though direct evidence in adults at standard doses is limited. The concern is more theoretically grounded than empirically confirmed for healthy adults, but it is not invented.

In the endocrine literature, a few specific interactions have received attention. The 2019 systematic review found evidence of effects on reproductive parameters and glucose metabolism at certain doses — both classified as dose- and timing-dependent rather than inherent to melatonin at physiological levels. Melatonin may lower blood glucose levels in some people, which becomes a health risk specifically when combined with diabetes medications. For people without diabetes, this effect is unlikely to be clinically significant.

The question of whether melatonin suppresses the body's own production is one of the most frequently asked — and the evidence is reassuring. The majority of studies find that supplementation does not suppress natural melatonin production even after up to a year of use. MT1 and MT2 receptors — the targets for melatonin — do not trigger the same negative feedback suppression seen with steroid hormones. A 2018 study found that circadian melatonin rhythms recovered to normal within 3 days of stopping supplementation. The "shut down your pineal gland" concern circulating online is not well-supported by current evidence.

3. Cardiovascular Risks: The 2025 AHA Study Explained

The most significant recent development in melatonin safety is a preliminary study presented at the American Heart Association's Scientific Sessions 2025. Researchers reviewed five years of health records for 130,828 adults with chronic insomnia. Those who used melatonin for at least one year had a 90% higher incidence of heart failure diagnosis (4.6% vs 2.7%), were 3.44 times more likely to be hospitalised for heart failure, and had 2.09 times higher all-cause mortality compared to matched non-users. These numbers are large enough to warrant serious attention.

The study has important limitations that must accompany those statistics. It was observational — meaning it measured association, not cause and effect. The entire study population had chronic insomnia, which is itself an established independent risk factor for cardiovascular disease. People who sleep poorly for years have higher heart rates, higher blood pressure, and more cardiovascular events regardless of what they take for sleep. The researchers acknowledged the study cannot prove melatonin caused the outcomes. The Council for Responsible Nutrition noted the findings are unlikely to apply to healthy adults using melatonin occasionally — the population melatonin supplements are marketed to. The study also has not yet been published in a peer-reviewed journal.

The honest summary: there is a preliminary signal worth monitoring, not a confirmed health risk warranting immediate alarm. What the study does reinforce clearly is that melatonin is not an appropriate long-term treatment for chronic insomnia — which was never its intended use. Using melatonin nightly for years to manage a serious sleep disorder, without medical oversight, carries risks that go beyond the supplement itself. If you have chronic insomnia, a sleep medicine physician is the right resource, not an OTC supplement.

4. Drug Interactions That Cause Health Problems

For people on prescription medications, melatonin's OTC status creates a false sense of safety. Drugs.com's clinical database lists 354 documented drug interactions with melatonin — 5 of them classified as major. These interactions are real health risks, not theoretical cautions. The five categories requiring the most attention:

• Blood thinners (warfarin, anticoagulants): Melatonin can increase bleeding risk. A 10-patient case series found concurrent melatonin and warfarin use increased INR and prothrombin time — markers for bleeding risk — in most participants. Signs of serious bleeding require immediate medical attention.
• Antidepressants (especially fluvoxamine): Fluvoxamine can elevate blood melatonin levels by 2.8 to 12 times, amplifying sedation and side effects. SSRIs combined with melatonin carry a theoretical risk of serotonin syndrome.
• Blood pressure medications: The Mayo Clinic documents that melatonin can worsen blood pressure control in people taking antihypertensives, and may reduce the effectiveness of nifedipine (a calcium channel blocker) specifically.
• Anticonvulsants: Melatonin may reduce the effectiveness of seizure medications and increase seizure frequency, particularly in children with neurological disabilities.
• Immunosuppressants: Melatonin can activate immune function, potentially undermining the effectiveness of immunosuppressant drugs used in transplant patients and autoimmune conditions.

The guidance here is straightforward: before adding melatonin to your routine, have a pharmacist or physician check your complete medication list. This is not optional for anyone on blood thinners, anticonvulsants, or immunosuppressants — those are the categories where the interaction rises to the major classification level. For most people on common medications, the interaction is lower-risk but still worth a professional check.

5. Special Risks in Children and Adolescents

Children represent the population where melatonin's health risks are least understood and most concerning. Use among children has grown sharply — and the NIH notes that because melatonin is a hormone, it could affect hormonal development, including puberty timing and menstrual cycles in young users. This is not a proven harm at typical doses, but it is an unstudied risk — there are no long-term clinical trials examining what melatonin does to hormonal development in children taking it for years.

A 2023 Lancet-family systematic review using GRADE methodology found that children treated with melatonin had a relative risk of 1.56 for non-serious adverse events compared to placebo — 56% more likely to experience side effects. No serious adverse events were attributed to melatonin in the studies reviewed. The researchers were explicit, however, that this "major gap of knowledge on safety calls for caution against complacent use of melatonin in children and adolescents."

Mislabelling poses a compounded risk in children. A 2024 FDA-led study of 110 melatonin supplements marketed for children found doses ranging from 0% to 667% of the stated label amount — an extraordinary variance in a product being given to young children whose bodies are far more sensitive to hormonal inputs than adults. A poison control center review of over 52,000 recorded cases of children taking melatonin found 15% required hospital evaluation. Paediatric melatonin use should always involve a paediatrician and should use products with third-party verified dosing.

6. The Mislabelling Risk: Taking More Than You Know

One of the most direct causes of melatonin-related health problems is rarely framed as a melatonin problem at all — it is a product quality problem. A JAMA-published study of 25 melatonin gummy products found 88% were inaccurately labelled, with actual melatonin content ranging from 74% to 347% of the stated dose. A broader analysis of commercially available supplements found melatonin content ranging from -83% to +478% of label claims. In the most extreme documented case, a product labelled at one dose contained nearly 5 times more melatonin than stated.

This matters for health because the symptoms most commonly attributed to melatonin — severe next-morning grogginess, prolonged sedation, disrupted circadian rhythms, and heightened side effect rates — are consistent with inadvertent overdose. If you buy a 3mg gummy that actually contains 10mg, you are taking a supraphysiological dose without knowing it. The FDA does not require supplement manufacturers to verify label accuracy before going to market. A separate analysis of melatonin supplements found that more than 1 in 4 products tested contained unlabelled serotonin — a hormone that produces adverse effects at low levels and interacts with multiple medications. Serotonin contamination is a distinct quality problem from mislabelling, and both have been documented across independently tested supplement batches.

The solution is third-party testing with a Certificate of Analysis (COA) confirming actual melatonin content — a step that is voluntary in the US market but eliminates the labelling accuracy problem entirely. In Canada, natural health products regulated by Health Canada require pre-market quality verification that US dietary supplements do not. When evaluating any melatonin product, looking for a Canadian NPN (Natural Product Number) or independent COA is the best proxy for dose accuracy.

7. Reducing Melatonin Health Risks Through Dose Precision

The health risks associated with melatonin can largely be mapped to two failure points: taking too much and not knowing what you're actually taking. Both are structural problems with how melatonin is manufactured and sold, not inherent properties of the molecule itself. The risk-reduction strategy follows directly from that framing — use the lowest effective dose, in a format that makes precise dosing possible, from a product with verified content. BioAbsorb's Liposomal Liquid Melatonin was built around exactly this logic.

Standard oral tablets and gummies have approximately 15–20% bioavailability — the rest is lost to digestion before reaching the bloodstream. To achieve a meaningful effect, manufacturers package large doses. BioAbsorb's liposomal delivery achieves 80–95% bioavailability, which means a 1.5mg dose delivers what would require 8–12mg in tablet form — without the residual hormone load that suppresses morning alertness. Onset is 15–30 minutes versus 60–90 minutes for tablets, giving users tighter control over timing. The graduated dropper allows dosing at 0.25mg increments from a starting point of 0.25mg — making the low-dose, titrated approach that researchers recommend practically achievable.

Every batch of BioAbsorb Liposomal Melatonin is third-party tested, with a Certificate of Analysis available on request — the independent verification step that addresses the JAMA mislabelling finding directly. The product is manufactured in a Health Canada-approved, GMP-certified facility in Canada, under the pre-market quality standards that Canadian natural health product regulation requires. The formulation is non-GMO, vegan, gluten-free, and free of artificial additives. At $29.99 for 100 servings (100ml), the per-serving cost is $0.30 — at a dose that is a fraction of what most retail products contain.

Frequently Asked Questions

Can melatonin damage your liver or kidneys?

At standard doses, there is no established evidence that melatonin causes liver or kidney damage. The research on chronic melatonin administration finds no clinically significant organ toxicity at doses of 5mg or less per day. At extremely high doses (250mg+ per day), used in some research contexts, adverse effects become more likely — but these are far above any reasonable consumer dose. Melatonin is considered one of the least toxic substances in pharmacology, though this characterisation applies to normal dosing ranges.

Does melatonin cause depression or mood changes?

At normal doses (≤5mg/day), melatonin has not been consistently linked to depression or mood disorders. Research notes that extremely high doses (250–1200mg/day) have been reported to worsen depression and bipolar disorder in case reports — but a study of patients with depression using 0.5–6mg daily for up to 3.5 years found no worsening of mood. If you are on antidepressants, the drug interaction concern is more pressing than a direct mood effect from melatonin itself.

Is melatonin harmful for older adults?

Older adults are more sensitive to melatonin because natural melatonin production declines with age and drug metabolism slows, meaning supplemental melatonin stays active longer in the body. A 2023 peer-reviewed review on melatonin in older adults found that adverse events were mild across the dosing range studied (0.3–15mg/day), but recommends starting at the lowest possible dose — 0.5mg — and monitoring carefully. Fall risk is a concern if melatonin causes significant next-morning grogginess in older users. Medical review is advisable before starting melatonin over 65.

What are the symptoms of taking too much melatonin?

Melatonin overdose produces a predictable cluster of symptoms: severe daytime grogginess, headache, nausea, dizziness, and in extreme cases, disorientation. A published case report documented a 16-year-old who ingested 900mg — extreme by any standard — and experienced significant sedation for 32 hours before recovering. At common OTC doses (5–10mg), an overdose is unlikely to be dangerous but will typically cause prolonged grogginess and disrupted sleep patterns in the days following. Because 88% of products are mislabelled, an "overdose" may occur without the user realising they took more than the label stated.

Can melatonin affect your blood pressure?

Yes — and this is one of the more nuanced interactions. Melatonin can lower blood pressure by approximately 3–5 mmHg, which may compound the effect of antihypertensive medications and push pressure too low. However, the Mayo Clinic also notes that melatonin can worsen blood pressure control in some people on antihypertensives — particularly with the calcium channel blocker nifedipine, where the interaction can reduce medication effectiveness. If you are managing blood pressure with medication, this interaction warrants a physician conversation before adding melatonin.

Is melatonin safe to stop suddenly?

Yes. Melatonin does not cause physical dependence and has no withdrawal syndrome — unlike benzodiazepines or Z-drugs (such as zolpidem). A 2023 peer-reviewed review confirmed that melatonin has a very low risk of dependence or withdrawal effects. The only documented exception was a single case report of movement disorder and agitation following melatonin withdrawal in a patient with severe cerebral palsy — an atypical neurological context not applicable to the general population. You can stop taking melatonin at any time without tapering.

Conclusion

Melatonin causes documented health problems — primarily mild side effects at appropriate doses, significant drug interactions for specific medication users, and compounded risks in children where long-term data is absent. The most underappreciated health risk is the mislabelling problem: when 88% of products contain a different dose than stated, it's impossible to know what you're actually taking. The path to using melatonin safely runs through verified content, low doses, and precision control — not through dismissing the concerns or through the exaggerated alarm that dominates most coverage of this topic.

Research References

1. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review. Journal of Sleep Research (2019). Gold-standard RCT-based evidence: daytime sleepiness 1.66%, headache 0.74%, dizziness 0.74% in 2,130 patients; no life-threatening events identified at any dose studied.
2. Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. PubMed-indexed systematic review (2019). Confirmed generally favourable safety profile; identified dose- and timing-dependent endocrine and cardiovascular effects; most adverse effects avoidable through circadian-aligned dosing.
3. Melatonin: What You Need to Know. National Center for Complementary and Integrative Health — NIH (2022). Authoritative government overview; confirms potential hormonal effects, drug interactions, and children's risk; affirms short-term safety for most adults.
4. Chronic Administration of Melatonin: Physiological and Clinical Considerations. PMC (2022 narrative review). Confirmed ≤5mg/day appears safe long-term; doses above 250mg/day linked to mood disorder worsening; no endogenous production suppression at typical doses.
5. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clinical Interventions in Aging, Vol. 18 (2023). Peer-reviewed analysis confirming mild, manageable adverse event profile in older adults; starting dose of 0.5mg recommended for this population.
6. The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment. eClinicalMedicine (The Lancet), Vol. 62 (2023). Found 1.56x higher non-serious adverse event risk vs. placebo in children; no serious events; long-term hormonal consequences in children remain unstudied.
7. Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia. American Heart Association Scientific Sessions 2025 (preliminary abstract, not yet peer-reviewed). Observational study of 130,828 insomnia patients: 90% higher heart failure incidence, 3.44x hospitalisation rate, 2.09x mortality in long-term melatonin users; causation not established.
8. Melatonin content of commercially available supplements in the United States. JAMA (2023). 88% of gummy products mislabelled; actual content 74%–347% of stated dose; raises significant consumer safety concerns about dose accuracy in OTC melatonin products.
9. Does supplemental melatonin suppress endogenous melatonin production?. InPharmD clinical review. Majority of studies find no suppression of natural production with up to 1 year of use; 2018 study confirmed recovery to normal circadian rhythms within 3 days of stopping.
10. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. Journal of Clinical Sleep Medicine (2017). Analysis of melatonin supplement batches found unlabelled serotonin present in more than 1 in 4 products tested; documented the dual contamination risk of dose inaccuracy and undisclosed active ingredients in unregulated supplement products.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.